Sugi Predict

Sugi Predict / Compounds / SCHEMBL573710

SCHEMBL573710

SCHEMBL573710

CCOC(=O)CC[C@@H](N)C(=O)OCC

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 2/20 0.53
▸ KMT2A Q03164 2/20 0.50
▸ POLB P06746 1/20 0.50
▸ CYP1A2 P05177 1/20 0.50
▸ GAA P10253 2/20 0.44
▸ MGAM O43451 1/20 0.44
▸ SI P14410 1/20 0.44
▸ MGAM2 Q2M2H8 1/20 0.44
▸ ALDH1A1 P00352 4/20 0.41
▸ TRPA1 O75762 1/20 0.41
▸ NOD1 Q9Y239 2/20 0.40
▸ ALOX15 P16050 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ CYP4F2 P78329 1/20 0.38
▸ CYP4A11 Q02928 1/20 0.38
▸ SLC1A1 P43005 1/20 0.37
▸ NR1I2 O75469 1/20 0.37
▸ PGR P06401 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL207116 1.00 L3MBTL1 (0.53) L3MBTL1KMT2APOLBCYP1A2GAA
SCHEMBL374738 1.00 L3MBTL1 (0.53) L3MBTL1KMT2APOLBCYP1A2GAA
Hydrochloric Acid SCHEMBL134418 0.98 L3MBTL1 (0.51) L3MBTL1KMT2APOLBCYP1A2GAA
Hydrochloric Acid SCHEMBL2012219 0.98 L3MBTL1 (0.51) L3MBTL1KMT2APOLBCYP1A2GAA
Hydrochloric Acid SCHEMBL134419 0.98 L3MBTL1 (0.51) L3MBTL1KMT2APOLBCYP1A2GAA
SCHEMBL20270768 0.98 L3MBTL1 (0.51) L3MBTL1KMT2APOLBCYP1A2GAA
Hydrochloric Acid SCHEMBL6845675 0.96 L3MBTL1 (0.50) L3MBTL1KMT2APOLBCYP1A2GAA
Ethyne SCHEMBL28180627 0.96 L3MBTL1 (0.50) L3MBTL1KMT2APOLBCYP1A2GAA
Acetic Acid SCHEMBL28340742 0.94 L3MBTL1 (0.49) L3MBTL1KMT2APOLBCYP1A2GAA
Ethyne SCHEMBL28279649 0.94 L3MBTL1 (0.49) L3MBTL1KMT2APOLBCYP1A2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 391 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119375325-A Electrochemical FET sensor 曲莱博医疗有限公司 2025-01-28 — — CN claimed
US-12188894-B2 Electrochemical FET sensor QULAB MEDICAL LTD. (IL) 2025-01-07 — — US claimed
CN-114364976-B Electrochemical FET sensor 曲莱博医疗有限公司 2024-11-12 — — CN claimed
CN-115737938-A Polyamino acid composite guided bone regeneration membrane for alveolar bone defect repair and preparation method thereof 上海大学 2023-03-07 — — CN claimed
CN-115518197-A Polyamino acid nanofiber open hollow microcarrier for bone defect repair, and preparation method and application thereof 上海大学 2022-12-27 — — CN claimed
CN-102424679-A Preparation method of Raltitrexed YANGTZE RIVER PHARM GROUP CO 2012-04-25 — — CN claimed
CN-102127063-A New synthesis technology of anti-cancer drug Raltitrexed SHENZHEN PUMAIDA TECHNOLOGY CO LTD 2011-07-20 — — CN claimed
CN-101560206-B Intermediate of pemetrexed disodium, preparation method thereof and method for preparing pemetrexed disodium thereby Suzhou lixin pharmaceutical co ltd 2011-06-22 — — CN claimed
US-20110124861-A1 Process for Preparing Pemetrexed Disodium and Its Intermediate, 4-(4-Carbomethoxyphenyl) Butanal SHANGHAI CDYMAX PHARMACEUTICALS CO., LTD (CN) 2011-05-26 — — US claimed
EP-2301909-A1 PROCESSES FOR PREPARING PEMETREXED DISODIUM AND ITS INTERMEDIATE,4-(4-CARBOMETHOXYPHENYL)BUTANAL Shanghai Cdymax Pharmaceuticals Co., Ltd (CN) 2011-03-30 — — EP claimed
CN-101560206-A Intermediate of pemetrexed disodium, preparation method thereof and method for preparing pemetrexed disodium thereby SUZHOU LIXIN PHARMACEUTICAL CO (CN) 2009-10-21 — — CN claimed
CN-101088997-A Improved process of preparing Raltitrexed XIUHUA WEI (CN) 2007-12-19 — — CN claimed
CN-1962658-A Tetrahydropyridine [3,2-d] pyridine compound and its uses for preparing antineoplastic drug UNIV BEIJING (CN) 2007-05-16 — — CN claimed
CN-1024007-C Process for preparing condensed pyrimidine TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1994-03-16 — — CN claimed
EP-0254726-A1 1,L-10-ethyl-10-deazaminopterin and process for preparing diastereoisomers of 10-alkyl-10-deazaminopterins SRI INTERNATIONAL (US) 1988-02-03 — — EP claimed
WO-1987004161-A1 DIASTEREOMERS OF 10-ALKYL-10-DIAZAMINOPTERINS AND PROCESS FOR PREPARING THE SAME SRI INTERNATIONAL (US) 1987-07-16 — — WO claimed
JP-9291152-A — — None — — JP disclosed
EP-4676964-A1 ANTIBODIES AND USES THEREOF Fusion Antibodies Plc (GB) 2026-01-14 — — EP disclosed
US-4263428-A LINKING TWO ANTIBIOTICS WITH A DIHYDRAZIDE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1981-04-21 — — US disclosed
EP-0004467-A2 Bis-anthracyclines, methods of making and using them and liposome compositions for administering them THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1979-10-03 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124861-A1 Process for Preparing Pemetrexed Disodium and Its Intermediate, 4-(4-Carbomethoxyphenyl) Butanal BPGM, PCNA, BRD1 L3MBTL1 2361/4885KMT2A 997/4885POLB 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.